Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 6Neuroendocrine Tumors 5Neoplasm Metastasis 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Tuberous Sclerosis 2Triple Negative Breast Neoplasms 2Recurrence 2Glioma 2Adenoma, Islet Cell 2von Hippel-Lindau Disease 1Vascular Malformations 1Unilateral Breast Neoplasms 1Thymus Neoplasms 1Seizures 1Sarcoma, Kaposi 1Sarcoma 1Nevus 1Myelodysplastic Syndromes 1Multiple Endocrine Neoplasia Type 1 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Lymphangioma 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Kidney Neoplasms 1Hormone Receptor Positive Breast Cancer 1Hemangioma 1Hemangioendothelioma 1

Interventions

Cyclophosphamide 3Gemcitabine 2regorafenib 1liposomal doxorubicin 1lenvatinib 1fludarabine 1alectinib 1aldesleukin 1Weight-Bearing 1Taxes 1Surveys and Questionnaires 1Restraint, Physical 1Range of Motion, Articular 1Quality of Life 1Proton Therapy 1Platinum 1Paclitaxel 1Nivolumab 1Metastasectomy 1Masks 1Lomustine 1Irinotecan 1Ipilimumab 1Everolimus 1Etoposide 1Doxorubicin 1Data Collection 1Cisplatin 1Carboplatin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bone Neoplasms × Everolimus × 90 days × Clear all
NCT07619950 2026-06-02

EVERolimus and LenvAtinib Versus Everolimus for Bone Sarcoma

Yonsei University

Phase 2 Not yet recruiting
94 enrolled
Sarcoma

Bone Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡